Profile data is unavailable for this security.
About the company
Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.
- Revenue in USD (TTM)1.66bn
- Net income in USD519.16m
- Incorporated2011
- Employees2.10k
- LocationAlkermes PlcConnaught HSE, 1 Burlington RoadDUBLIN 00000IrelandIRL
- Phone+353 17728000
- Websitehttps://www.alkermes.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 10X Genomics Inc | 625.45m | -264.30m | 3.49bn | 1.26k | -- | 4.85 | -- | 5.58 | -2.24 | -2.24 | 5.30 | 6.04 | 0.6458 | 2.68 | 7.39 | 496,781.60 | -27.29 | -25.52 | -30.80 | -29.05 | 64.57 | 75.88 | -42.26 | -48.53 | 4.45 | -- | -- | -- | 19.81 | 33.43 | -53.67 | -- | 49.15 | -- |
| Axsome Therapeutics Inc | 270.60m | -239.24m | 3.49bn | 545.00 | -- | 18.29 | -- | 12.91 | -5.20 | -5.20 | 5.96 | 4.03 | 0.5885 | 2.68 | 4.08 | 496,513.80 | -52.02 | -64.55 | -69.92 | -82.23 | 90.37 | -- | -88.41 | -227.05 | 3.52 | -35.93 | 0.4825 | -- | 440.80 | -- | -27.84 | -- | 77.86 | -- |
| Ultragenyx Pharmaceutical Inc | 434.25m | -606.64m | 3.50bn | 1.28k | -- | 12.71 | -- | 8.07 | -8.33 | -8.33 | 5.91 | 3.35 | 0.286 | 1.49 | 7.63 | 340,320.50 | -39.96 | -33.35 | -48.63 | -38.30 | 89.59 | 93.13 | -139.70 | -154.71 | 2.49 | -- | 0.00 | -- | 19.52 | 53.18 | 14.25 | -- | 62.91 | -- |
| Simply Good Foods Co | 1.27bn | 140.76m | 3.64bn | 271.00 | 26.17 | 2.21 | 22.51 | 2.88 | 1.39 | 1.39 | 12.53 | 16.48 | 0.5977 | 6.91 | 8.56 | 4,671,908.00 | 6.65 | 3.66 | 6.95 | 3.83 | 37.26 | 38.90 | 11.12 | 6.80 | 3.09 | 9.26 | 0.1261 | 0.00 | 6.33 | 23.56 | 23.03 | 13.65 | 47.09 | -- |
| Insmed Inc | 305.21m | -749.57m | 3.67bn | 912.00 | -- | -- | -- | 12.03 | -5.35 | -5.35 | 2.17 | -2.24 | 0.2044 | 0.8562 | 8.61 | 334,657.90 | -50.20 | -40.96 | -58.32 | -46.88 | 78.52 | 77.99 | -245.59 | -212.92 | 3.75 | -17.21 | 1.39 | -- | 24.39 | 98.78 | -55.66 | -- | -2.15 | -- |
| Alvotech SA | 93.38m | -551.73m | 3.87bn | 999.00 | -- | -- | -- | 41.43 | -2.40 | -2.40 | 0.4109 | -3.49 | 0.105 | 2.20 | 1.39 | 93,475.48 | -62.04 | -- | -81.72 | -- | -72.26 | -- | -590.83 | -- | 0.4614 | -1.29 | 7.52 | -- | 9.84 | -- | -7.43 | -- | -- | -- |
| Immunovant Inc | 0.00 | -243.45m | 3.99bn | 164.00 | -- | 5.86 | -- | -- | -1.83 | -1.83 | 0.00 | 4.68 | 0.00 | -- | -- | 0.00 | -41.70 | -- | -44.49 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -34.60 | -- | -- | -- |
| Alkermes Plc | 1.66bn | 519.16m | 4.15bn | 2.10k | 8.12 | 3.41 | 6.99 | 2.50 | 3.02 | 2.07 | 9.79 | 7.20 | 0.8114 | 1.38 | 5.28 | 792,097.60 | 25.32 | 1.34 | 33.69 | 1.74 | 84.79 | 83.32 | 31.21 | 2.12 | 2.50 | -- | 0.1947 | 0.00 | 49.61 | 8.74 | 1,665.99 | -- | -7.10 | -- |
| Alpine Immune Sciences Inc | 58.88m | -32.18m | 4.23bn | 142.00 | -- | 11.89 | -- | 71.91 | -0.6827 | -0.6827 | 1.18 | 5.43 | 0.1767 | -- | 210.65 | 414,619.70 | -9.66 | -21.93 | -11.36 | -27.81 | -- | -- | -54.66 | -170.16 | -- | -- | 0.00 | -- | 95.84 | 142.30 | 44.28 | -- | -0.3253 | -- |
| Madrigal Pharmaceuticals Inc | 0.00 | -373.63m | 4.34bn | 376.00 | -- | 10.00 | -- | -- | -19.93 | -19.93 | 0.00 | 20.39 | 0.00 | -- | -- | 0.00 | -74.49 | -62.09 | -97.21 | -74.81 | -- | -- | -- | -- | -- | -- | 0.2217 | -- | -- | -- | -26.50 | -- | 132.01 | -- |
| Krystal Biotech Inc | 50.70m | 10.93m | 4.37bn | 229.00 | 1,730.37 | 5.55 | 258.81 | 86.12 | 0.0885 | 0.0885 | 1.84 | 27.58 | 0.0737 | -- | -- | 221,393.00 | 1.59 | -11.50 | 1.66 | -12.01 | 93.90 | -- | 21.56 | -492.85 | 17.55 | -- | 0.00 | -- | -- | -- | 107.81 | -- | 39.49 | -- |
| Nuvalent Inc | 0.00 | -126.22m | 4.45bn | 92.00 | -- | 6.30 | -- | -- | -2.16 | -2.16 | 0.00 | 10.94 | 0.00 | -- | -- | 0.00 | -20.78 | -- | -21.70 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.20 | -- | -- | -- |
| Organon & Co | 6.26bn | 1.02bn | 4.76bn | 10.00k | 4.66 | -- | 3.78 | 0.7596 | 3.99 | 3.99 | 24.44 | -0.2738 | 0.5443 | 2.17 | 3.89 | 626,300.00 | 8.89 | 16.53 | 11.64 | 20.97 | 59.84 | 65.12 | 16.33 | 26.79 | 1.09 | 2.31 | 1.01 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.72 | -- |
| BridgeBio Pharma Inc | 9.30m | -643.20m | 4.79bn | 550.00 | -- | -- | -- | 515.34 | -3.95 | -3.95 | 0.0572 | -7.73 | 0.0159 | -- | -- | 16,914.54 | -111.72 | -72.44 | -148.01 | -89.72 | 73.71 | 94.41 | -7,021.94 | -1,225.66 | -- | -13.34 | 4.49 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
| Halozyme Therapeutics, Inc. | 829.25m | 281.59m | 4.84bn | 373.00 | 18.07 | 57.63 | 13.30 | 5.84 | 2.11 | 2.11 | 6.18 | 0.6611 | 0.464 | 1.69 | 3.56 | 2,223,199.00 | 15.75 | 18.22 | 16.90 | 21.97 | 76.80 | 79.05 | 33.96 | 39.36 | 5.50 | 139.09 | 0.9471 | 0.00 | 25.62 | 40.43 | 39.31 | -- | 26.82 | -- |
Data as of May 01 2024. Currency figures normalised to Alkermes Plc's reporting currency: US Dollar USD
59.68%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2023 | 26.27m | 15.73% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 20.48m | 12.26% |
| Wellington Management Co. LLPas of 31 Dec 2023 | 15.24m | 9.12% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 9.35m | 5.60% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 6.05m | 3.62% |
| Hardman Johnston Global Advisors LLCas of 31 Dec 2023 | 5.48m | 3.28% |
| Pictet Asset Management SAas of 31 Dec 2023 | 5.30m | 3.18% |
| Deep Track Capital LPas of 31 Dec 2023 | 4.00m | 2.39% |
| RTW Investments LPas of 31 Dec 2023 | 3.90m | 2.34% |
| Geode Capital Management LLCas of 31 Dec 2023 | 3.64m | 2.18% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
